HAE
Haemonetics Corporation
HAE trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over HAE overall, supported by stronger fundamentals and stronger valuation.
HAE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Under pressure |
HAE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HAE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $56.99 | -54% |
| Fair | 41x | $93.28 | -24% |
| Current | 54x | $123 | — |
| Expensive | 66x | $150 | +22% |
Historical ranges are pointers, not guarantees.
HAE's PE is in its expensive range at 54x.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over HAE in the historical PE scenario, which offers more potential upside but is not a forecast.
HAE Forward outlook
There aren't enough analyst estimates for HAE to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HAE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.26 | -34% |
| Q2 2026 | $2.07 | -37% |
| Q1 2026 | $2.05 | -38% |
| Q4 2025 | $3.63 | +43% |
| Q3 2025 | $3.42 | +42% |
| Q2 2025 | $3.27 | +47% |
| Q1 2025 | $3.31 | +45% |
| Q4 2024 | $2.54 | +2.8% |
HAE earned $2.26 per share over the past year, down 34% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HAE on earnings, with more consistent year-over-year improvement.
HAE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +9.3% |
| Q2 2026 | $339.4M | +5.6% |
| Q1 2026 | $346.4M | +4.8% |
| Q4 2025 | $339M | -2.7% |
| Q3 2025 | $327.3M | -5.3% |
| Q2 2025 | $321.4M | -4.4% |
| Q1 2025 | $330.6M | -3.7% |
| Q4 2024 | $348.5M | +3.7% |
HAE's revenue has picked up after two years of holding roughly level: $358M last quarter, up 9.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +3.1 points |
| Q2 2026 | 17% | +0.2 points |
| Q1 2026 | -6.7% | -28 points |
| Q4 2025 | 20% | +2.9 points |
| Q3 2025 | 18% | +2.9 points |
| Q2 2025 | 17% | +4.9 points |
| Q1 2025 | 22% | +13 points |
| Q4 2024 | 17% | +3.3 points |
HAE's operating margin was 21% last quarter, up 3.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HAE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HAE on profitability, with a higher operating margin.
HAE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $113.3M | +6.6% |
| Q2 2026 | $44.4M | +226% |
| Q1 2026 | $53.3M | -47% |
| Q4 2025 | $87.2M | +148% |
| Q3 2025 | $106.3M | +170% |
| Q2 2025 | $13.6M | +$46.7M |
| Q1 2025 | $100.9M | +86% |
| Q4 2024 | $35.2M | +$58.1M |
HAE has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
HAE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +759K shares |
| 1 year | -2.5% | -1.2M shares |
| 3 years | -9.6% | -4.9M shares |
| 5 years | -9.7% | -5M shares |
| Available history | -10% | -5.2M shares |
HAE has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q1 2025 | $150M |
| Q4 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HAE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 3.1x | Elevated |
HAE's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over HAE on leverage, with a lower net debt burden relative to earnings.
HAE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.5 | Overbought |
| Stochastic | 82.3 | Overbought |
HAE's weekly RSI is 79 (overbought) and its Stochastic is 82 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HAE PE vs Healthcare Sector
| Metric | HAE | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 110% above |
| PE % | 67 | 29 | 38 pts above |
HAE is trading at 54x earnings, a 110% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over HAE on valuation relative to its sector.
HAE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.0 | 5.8% above |
| 20 week MA | $101.3 | 21% above |
| 50 week MA | $80.9 | 52% above |
| 100 week MA | $72.9 | 68% above |
| 200 week MA | $78.4 | 57% above |
HAE has climbed back above all five of its weekly moving averages, and it's now 57% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
HAE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.9 | $118.8 | +2.4% |
| 2021 | $118.8 | $54.2 | -54% |
| 2022 | $54.2 | $79.2 | +46% |
| 2023 | $79.2 | $85.5 | +8% |
| 2024 | $85.5 | $77.6 | -9.3% |
| 2025 | $77.6 | $80.3 | +3.5% |
| 2026 YTD | $80.3 | $122.7 | +53% |
HAE has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.